EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)

A global phase II randomized trial comparing oral taxane ModraDoc006/r to intravenous docetaxel in metastatic castration resistant prostate cancer

Ulka N Vaishampayan, Marianne Keessen, Robert Dreicer, Elisabeth I Heath, Tomas Buchler, Péter F Árkosy, Tibor Csöszi, Pawel Wiechno, Evgeny Kopyltsov, Sergey V Orlov, Alexey Plekhanov, Maria Smagina und 2 weitere

European Journal of Cancer · 2024-05 · 202 · 114007

DOI: 10.1016/j.ejca.2024.114007 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Cancer, 2024-05. Verfasst von Ulka N Vaishampayan und 13 weiteren Autor:innen. Beteiligte Einrichtung: University of Michigan Ann Arbor, MI, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Bridged-Ring Compounds. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantBridged-Ring CompoundsMaleHumansDocetaxelPrednisoneRitonavirTreatment OutcomeTaxoidsAntineoplastic Combined Chemotherapy ProtocolsProstate-Specific Antigen

Stichwörter der Autor:innen

ChemotherapyDocetaxelDrug discovery and deliveryOral taxaneProstate cancer

Substanzen

DocetaxelPrednisoneRitonavirtaxaneTaxoidsProstate-Specific AntigenBridged-Ring Compounds

Autor:innen und Institutionen

  • University of Michigan Ann Arbor, MI, USA.
  • Modra Pharmaceuticals B.V., Amsterdam, Netherlands. Electronic address: mariannekeessen@gmail.com.
  • University of Virginia, Charlottesville, VA, USA.
  • Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA.
  • Department of Oncology, First Faculty of Medicine, Charles University and Thomayer University Hospital, Prague, Czech Republic.
  • Debrecen Institute of Oncology, Debrecen, Hungary.

Zitieren

APA

Vaishampayan, U. N., Keessen, M., Dreicer, R., Heath, E. I., Buchler, T., Árkosy, P. F., Csöszi, T., Wiechno, P., Kopyltsov, E., Orlov, S. V., Plekhanov, A., Smagina, M., Varlamov, S., & Shore, N. D. (2024). A global phase II randomized trial comparing oral taxane ModraDoc006/r to intravenous docetaxel in metastatic castration resistant prostate cancer. European Journal of Cancer, 202, 114007. https://doi.org/10.1016/j.ejca.2024.114007

Vancouver

Vaishampayan UN, Keessen M, Dreicer R, Heath EI, Buchler T, Árkosy PF, et al. A global phase II randomized trial comparing oral taxane ModraDoc006/r to intravenous docetaxel in metastatic castration resistant prostate cancer. European Journal of Cancer. 2024;202:114007. doi:10.1016/j.ejca.2024.114007

BibTeX
@article{Vaishampayan2024,
  author = {Vaishampayan, Ulka N and Keessen, Marianne and Dreicer, Robert and Heath, Elisabeth I and Buchler, Tomas and Árkosy, Péter F and Csöszi, Tibor and Wiechno, Pawel and Kopyltsov, Evgeny and Orlov, Sergey V and Plekhanov, Alexey and Smagina, Maria and Varlamov, Sergei and Shore, Neal D},
  title = {A global phase II randomized trial comparing oral taxane ModraDoc006/r to intravenous docetaxel in metastatic castration resistant prostate cancer},
  journal = {European Journal of Cancer},
  year = {2024},
  volume = {202},
  pages = {114007},
  doi = {10.1016/j.ejca.2024.114007}
}
Kostenlos starten →